BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 12, 2015
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Vascular endothelial growth factor receptor 1 (FLT1; VEGFR-1); neuropilin 1 (NRP1)

Ophthalmic disease

Animal studies suggest local delivery of a small cyclic peptidomimetic inhibitor of FLT1 and NRP1 could help treat AMD and retinopathy of prematurity (ROP). In a monkey model of AMD, an eye drop formulation of vasotide -...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >